Explainer Episode 55 - 10 Years On: The Impact and Effects of AMP vs. Myriad
Regulatory Transparency Project's Fourth Branch Podcast
| Topics: | Administrative Law & Regulation • Healthcare • Regulatory Transparency Project |
|---|---|
| Sponsors: | Regulatory Transparency Project |
On June 13, 2013, the Supreme Court issued its unanimous decision in Association for Molecular Pathology v. Myriad Genetics Inc. a case that would ban attempts to patent naturally occurring DNA sequences.
Now, ten years down the line with a decade of hindsight, Dr. Roger Klein, who played a central role as an expert, advisor, and spokesperson for the Association for Molecular Pathology in AMP v. Myriad, joins us to discuss this important case. In this Explainer we discuss the context surrounding this case, the debates that arose, and the impact this rule had across the past 10 years.
Featuring:
- Dr. Roger D. Klein, Faculty Fellow, Center for Law, Science & Innovation Sandra Day O'Connor College of Law
Visit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.
*******
As always, the Federalist Society takes no position on particular legal or public policy issues; all expressions of opinion are those of the speaker.